Generation Bio Co. Files 8-K: Board and Executive Compensation Changes
| Field | Detail |
|---|---|
| Company | Generation Bio Co. |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $700,000, $300,000, $70,000, $500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Gen Bio's board is shuffling, exec pay is changing. Keep an eye on this.
AI Summary
On October 21, 2025, Generation Bio Co. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a departure of directors and the election of new ones, alongside updates to compensatory arrangements for certain officers. Specific details regarding the individuals involved and the financial implications of these changes were not fully elaborated in the provided text.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial stability.
Key Players & Entities
- Generation Bio Co. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- 301 Binney Street, Cambridge, MA 02142 (address) — Principal Executive Offices
- 001-39319 (other) — SEC File Number
FAQ
What specific changes were made to the board of directors of Generation Bio Co. on October 21, 2025?
The 8-K filing indicates a departure of directors and the election of new directors, but does not specify the names of those departing or newly elected in the provided text.
Were there any changes to the executive officers of Generation Bio Co. on October 21, 2025?
The filing mentions 'Appointment of Certain Officers' as an item of information, suggesting potential changes or confirmations regarding executive officers.
What is the nature of the updates to compensatory arrangements for Generation Bio Co. officers?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item of information, indicating that details regarding executive compensation have been updated or disclosed.
What is the principal business of Generation Bio Co.?
Generation Bio Co. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where are Generation Bio Co.'s principal executive offices located?
Generation Bio Co.'s principal executive offices are located at 301 Binney Street, Cambridge, MA 02142.
Filing Stats: 1,478 words · 6 min read · ~5 pages · Grade level 12.5 · Accepted 2025-10-22 16:13:53
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GBIO Nasdaq Glo
- $700,000 — of (i) cash severance of approximately $700,000, which is an amount equal to 12 months
- $300,000 — yment in lieu of bonus of approximately $300,000, which is an amount representing a pror
- $70,000 — ill be awarded a bonus of approximately $70,000 for the time he remained employed with
- $500 — nough an hourly consulting fee equal to $500 per hour for his services and any unves
- $575,000 — e will receive an annual base salary of $575,000 and her annual target bonus will be 50%
- $360 — mayoa an hourly consulting fee equal to $360 and $400 per hour, respectively, for th
- $400 — hourly consulting fee equal to $360 and $400 per hour, respectively, for their servi
Filing Documents
- gbio-20251021x8k.htm (8-K) — 45KB
- gbio-20251021xex99d1.htm (EX-99.1) — 9KB
- gbio-20251021xex99d1001.jpg (GRAPHIC) — 4KB
- 0001104659-25-101535.txt ( ) — 175KB
- gbio-20251021.xsd (EX-101.SCH) — 3KB
- gbio-20251021_def.xml (EX-101.DEF) — 3KB
- gbio-20251021_lab.xml (EX-101.LAB) — 14KB
- gbio-20251021_pre.xml (EX-101.PRE) — 11KB
- gbio-20251021x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Generation Bio Co. on October 22, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENERATION BIO CO. Date: October 22, 2025 By: /s/ Geoff McDonough Name: Geoff McDonough, M.D. Title: President and Chief Executive Officer